Medically Backed Fat Binding Weight Loss Product
 The biggest
problem faced by people who
are interested in
weight
loss products is the lack of
clinical studies that can
back up the effectiveness of
the product with incontrovertible
data collected according to
the scientific standards of
our age.
Proactol™ on the
other hand has taken the
right step by undergoing a
clinical research.
Below you
will find the list of the
clinical studies on
Proactol™ patented
ingredient (NeOpuntia®)
and its fat binding
properties.
-
Clinical Study 1 - Fat
binding capacity of
NeOpuntia® during
passage through a dynamic
gastrointestinal model
-
Clinical study 2 - Fat
binding capacity of xxx
during passage through a
dynamic gastrointestinal
model
-
Clinical Study 3 - Fat
binding capacity of
NeOpuntia® in an
American breakfast meal
during passage through a
dynamic gastrointestinal
model
-
Clinical Study 4 - Pilot
clinical study of
NeOpuntia® on fat
binding
(you may download the report
in pdf format on the left
sidebar for further info)
The Clinical Studies
Clinical Study 1 - Fat binding capacity of NeOpuntia® during passage through a dynamic gastrointestinal model
The Aim Of The Study
The aim of the study is to
determine the
fat binding capacity of NeOpuntia® during passage through a dynamic, computer controlled model of the stomach and
small intestine.
The Findings
The result shows that 2 grams of
NeOpuntia® prevented the absorption of 2.7 grams of fatty acids during the 4 hours of experiment in TNO gastro-Intestinal Model.
The percentage bound to the
NeOpuntia® is not selective for specific fatty acids.
Clinical Study 2 - Fat binding capacity of xxx during passage through a dynamic gastrointestinal model
The Aim Of The Study
The aim of the study is to
determine the
fat binding capacity of xxx during passage through the gastric and
small intestine model.
The Findings
The result shows that xxx showed no effect on the
bioaccessibility of fatty acids, in contrast to NeOpuntia® that decreased the removed fraction of fatty acids.
Clinical Study 3 - Fat binding capacity of NeOpuntia® in an American breakfast meal during passage through a dynamic gastrointestinal model
The Aim Of The Study
The aim of the study is to
determine the
fat binding capacity of NeOpuntia® added to an American breakfast meal during passage through a dynamic, computer controlled model of the stomach and
small intestine.
The Findings
NeOpuntia® mixed directly with the fat of a meal gives a successfull reduction of lipid absorption.
Clinical Study 4 - Pilot Clinical Study of NeOpuntia® on Fat Binding
The Aim Of The Study
The aim of the study is to
determine the
fat binding capacity of NeOpuntia®
The Method
10 healthy volunteers (5
women and 5 men with a Body
Mass Index of 23.3 Kg/m2;
standard deviations 3.1)
participated in a
monocentric double-blind
placebo controlled crossover
study.
The test participants were
randomly divided into two
groups, one receiving
NeOpuntia® and one
receiving placebo. All the
volunteers consumed 1.6g of
NeOpuntia® per meal
in the form of capsule,
during one week and placebo
during the same time with a
washout period between this
two test periods. A strict
diet with standardized meals
was followed by the
volunteers to ensure a
standardized intake of
lipids.
The effect of the product
dose in intestinal
absorption fat was evaluated
by measuring steatorrhea in
3-day-old faeces, at the end
of the two 7-day product
consumption periods.
The Findings
The quantity of fat content
excreted compared to the
quantity ingested increased
on average by 27.4% in group
volunteers with the dose of
NeOpuntia® compared
with the placebo.
No side effects, or
particular discomfort were
observed with the
dose of NeOpuntia®.
The Breakthrough Weight Loss
Proactol™ is a clinically proven
medical device product (MDD 93/42/EEC) for the treatment of obesity.
Proactol™ is set to become
the most credible weight loss pill available without prescription online!
How Does Proactol™ Work
|
Accept No Substitute
Take
Your Weight Assessment Here | 
